Candesartan

Candesartan 16 mg Emerges as a Robust, Evidence-Based Option for Migraine Prophylaxis

A Phase 2 triple-blind trial confirms that 16 mg of candesartan daily significantly reduces monthly migraine days compared to placebo, offering a well-tolerated oral alternative for patients with episodic migraine.

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial